{"id":3812,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/caspofungin-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"caspofungin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/caspofungin-txt\/","title":{"rendered":"Caspofungin.txt"},"content":{"rendered":"

Caspofungin<\/h1>\n

CLINICAL USE <\/H3><\/p>\n
  • Invasive aspergillosis in adult patients who are refractory to or intolerant of amphotericin B and\/or itraconazole\n
  • Invasive candidiasis\n
  • Empirical treatment of systemic fungal infections in patients with neutropenia

    DOSE IN NORMAL RENAL FUNCTION <\/H3>70 mg loading dose on day 1 followed by 50 mg daily, thereafterIf patient weighs >80 kg use 70 mg daily

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :1213.4 (as acetate)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :97<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 1.4<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :No data<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :12\u201315 days\/Increased but not significantly.

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Ciclosporin: monitor liver enzymes as transient increases in ALT and AST have been reported with concomitant administration. Avoid co-administration if possible. Increases AUC of caspofungin by 35%\n
  • Tacrolimus: reduces tacrolimus trough concentration by 26%

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>10.5 mL water for injection

    Route <\/H4>

    IV infusion <\/H4>

    Rate of Administration <\/H4>Approximately 1 hour

    Comments<\/H4>\n
  • Caspofungin is unstable in fluids containing glucose; add to 250 mL sodium chloride 0.9% or lactated Ringer\u2019s solution\n
  • If patient is fluid restricted, doses of 35 or 50 mg may be added to 100 mL infusion fluid

    OTHER INFORMATION <\/H4>\n
  • In established renal failure the AUC is increased by 30\u201349% but a change in dosage schedule is not required\n
  • Plasma concentrations of caspofungin decline in a polyphasic manner. A short \u03b1-phase occurs immediately post infusion, followed by a \u03b2-phase with a half-life of 9\u201311 hours. An additional \u03b3-phase also occurs with a half-life of 40\u201350 hours. Distribution rather than excretion or biotransformation is the dominant mechanism influencing plasma clearance\n
  • Caspofungin has been used at a dose of 50 mg daily in combination with IV amphotericin B to successfully treat fungal peritonitis
    \n","protected":false},"excerpt":{"rendered":"

    Caspofungin CLINICAL USE Invasive aspergillosis in adult patients who are<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3812","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3812"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3812\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}